MX2020007271A - Sales y cristales novedosos. - Google Patents

Sales y cristales novedosos.

Info

Publication number
MX2020007271A
MX2020007271A MX2020007271A MX2020007271A MX2020007271A MX 2020007271 A MX2020007271 A MX 2020007271A MX 2020007271 A MX2020007271 A MX 2020007271A MX 2020007271 A MX2020007271 A MX 2020007271A MX 2020007271 A MX2020007271 A MX 2020007271A
Authority
MX
Mexico
Prior art keywords
crystals
novel salts
utan
quinoxalin
pyrido
Prior art date
Application number
MX2020007271A
Other languages
English (en)
Inventor
Lawrence P Wennogle
Peng Li
Edwin Aret
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of MX2020007271A publication Critical patent/MX2020007271A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

La divulgación provee formas de sal clorhidrato nuevas, farmacéuticamente aceptables, de 1-(4-fluoro-fenil)-4-((6bR,10aS)- 3-metil-2,3,6b,9,10,10a-hexahidro-1H,7H-pirido[3',4':4,5]pirrolo[ 1,2,3-de]quinoxalin-8-il)-butan-1-ona, junto con métodos de preparación y uso de las mismas, y composiciones farmacéuticas que las comprenden.
MX2020007271A 2017-09-26 2018-09-26 Sales y cristales novedosos. MX2020007271A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762563341P 2017-09-26 2017-09-26
PCT/US2018/052922 WO2019067591A1 (en) 2017-09-26 2018-09-26 NEW SALTS AND CRYSTALS

Publications (1)

Publication Number Publication Date
MX2020007271A true MX2020007271A (es) 2020-08-17

Family

ID=65903143

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007271A MX2020007271A (es) 2017-09-26 2018-09-26 Sales y cristales novedosos.

Country Status (6)

Country Link
US (2) US11440911B2 (es)
EP (1) EP3687535A4 (es)
JP (1) JP2020535231A (es)
CN (1) CN111107847A (es)
MX (1) MX2020007271A (es)
WO (1) WO2019067591A1 (es)

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2228549T3 (es) 1999-06-15 2005-04-16 Bristol-Myers Squibb Pharma Company Gamma-carbolinas condensadas con heterociclo sustituido.
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
US7071186B2 (en) 1999-06-15 2006-07-04 Bristol-Myers Squibb Pharma Co. Substituted heterocycle fused gamma-carbolines
US6849619B2 (en) 2000-12-20 2005-02-01 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
KR20030070073A (ko) 2000-12-20 2003-08-27 브리스톨-마이어스스퀴브컴파니 세로토닌 효능제 및 길항제로서의 치환된 피리도인돌
US6759554B2 (en) 2001-04-24 2004-07-06 Massachusetts Institute Of Technology Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds
BRPI0412763A (pt) 2003-07-21 2006-09-26 Smithkline Beecham Corp formas anidras, hidratadas ou solvatadas de um composto, forma cristalina, composição farmacêutica, e, método para o tratamento ou a profilaxia de distúrbios
DE602007003024D1 (de) * 2006-06-27 2009-12-10 Sandoz Ag Neues verfahren zur salzherstellung
CA2679754C (en) 2007-03-12 2018-08-07 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
CA2719824A1 (en) 2007-08-01 2009-02-05 Medivation Neurology, Inc. Methods and compositions for treating schizophrenia using antipsychotic combination therapy
KR20150140418A (ko) * 2008-03-12 2015-12-15 인트라-셀룰라 써래피스, 인코퍼레이티드. 치환된 헤테로사이클 융합 감마-카볼라인 고체
KR102133073B1 (ko) 2008-05-27 2020-07-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 수면 장애 및 다른 장애를 치료하기 위한 방법 및 조성물
RU2591194C2 (ru) 2010-04-22 2016-07-10 Интра-Селлулар Терапиз, Инк. Органические соединения
CN104519886B (zh) 2012-04-14 2017-09-12 细胞内治疗公司 有机化合物
WO2014145192A1 (en) 2013-03-15 2014-09-18 Intra-Cellular Therapies, Inc. Organic compounds
CA2932610C (en) 2013-12-03 2023-08-22 Intra-Cellular Therapies, Inc. Heterocycle fused gamma-carboline compounds for use in treatment of schizophrenia
PL3125893T3 (pl) 2014-04-04 2024-02-12 Intra-Cellular Therapies, Inc. Deuterowane gamma-karboliny w fuzji z heterocyklami jako antagoniści receptorów 5-HT2A
PT3407889T (pt) 2016-03-25 2021-07-14 Intra Cellular Therapies Inc Compostos orgânicos e a sua utilização no tratamento ou prevenção de distúrbios do sistema nervoso central
US10654854B2 (en) 2016-03-28 2020-05-19 Intra-Cellular Therapies, Inc. Salts and crystals of ITI-007
EP3436016B1 (en) 2016-03-28 2022-04-27 Intra-Cellular Therapies, Inc. Novel co-crystals
SI3497104T1 (sl) 2016-08-09 2021-12-31 Teva Pharmaceuticals International Gmbh Trdne oblike soli lumateperon ditosilata
AU2018240540B2 (en) 2017-03-24 2021-09-23 Intra-Cellular Therapies, Inc. Novel compositions and methods
EP3609501A4 (en) 2017-04-10 2020-08-19 Dr. Reddy's Laboratories Limited AMORPHIC FORM AND SOLID DISPERSIONS OF LUMATEPERONE P-TOSYLATE
EP3717484A4 (en) 2017-11-27 2021-08-04 Egis Gyógyszergyár Zrt. PROCESS FOR THE PRODUCTION OF LUMATEPERON AND ITS SALT
AU2019287460B2 (en) 2018-06-11 2024-02-15 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis

Also Published As

Publication number Publication date
US20200247805A1 (en) 2020-08-06
US20220363682A1 (en) 2022-11-17
CN111107847A (zh) 2020-05-05
JP2020535231A (ja) 2020-12-03
EP3687535A1 (en) 2020-08-05
US11440911B2 (en) 2022-09-13
EP3687535A4 (en) 2021-06-09
WO2019067591A1 (en) 2019-04-04

Similar Documents

Publication Publication Date Title
MX2020013116A (es) Sales y cristales novedosos.
MX2018011831A (es) Antagonistas solubles de receptor de c5aa(c5ar).
MX2022010797A (es) Composiciones novedosas y metodos.
CR20200064A (es) Carboxamidas como moduladores de los canales de sodio
MX2018015422A (es) Compuestos de indol sustituidos con [1,2,4]triazolo[1,5-a]piridini lo.
SA521430638B1 (ar) H مركبات بيرميدين-2-يل أمينو-1 lrrk2 بيرازول في صورة مثبطات لاستخدامها في علاج الاضطرابات التنكسية العصبية
PH12016501355B1 (en) Bicyclic heterocyclic derivatives as bromodomain inhibitors
PH12015502004A1 (en) Tetracyclic bromodomain inhibitors
MX2019002180A (es) Moduladores alostericos positivos del receptor m1 muscarinico.
PH12018500047B1 (en) Notch pathway signaling inhibitor compounds
MX2017013874A (es) Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.
PH12017501816A1 (en) Azabensimidazoles and their use as amp a receptor modulators
MY192216A (en) Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] pyrimidine-2,4-diamine
TW201613864A (en) Novel compounds
EP4249071A3 (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
MX2022013274A (es) Compuestos de triazolo-pirimidina fusionados que tienen aplicacion farmaceutica util.
MY194711A (en) Novel annelated phenoxyacetamides
MX2014013664A (es) N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxietil)ami no)-2-oxo-n-fenil-1,2-dihidroquinolin-3-carboxamida.
NZ763341A (en) Polycyclic amides as muscarinic m1 receptor positive allosteric modulators
MX2018014185A (es) Combinacion de antagonistas puros del receptor 5 ht6 con inhibidores de la acetilcolinesterasa.
NZ741553A (en) Dibenzo azepine compounds and their use in the treatment of otic diseases and disorders
NZ764004A (en) Heteroaryl compounds as muscarinic m1 receptor positive allosteric modulators
MX2021006886A (es) Dispersiones solidas amorfas.
PH12018501563A1 (en) Indane derivatives as mglur7 modulators
MX2020007271A (es) Sales y cristales novedosos.